Items Tagged ‘meastatic breast cancer’

January 6, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer


Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. […]

View full entry

Tags: antibody, Breast Cancer, Chemotherapy, combination therapy, HER2-positive, meastatic breast cancer, Metastatic Breast Cancer, News, T-DMI, TH3RESA trial, trastuzumab emtansine